ozanimod UC
Selected indexed studies
- Ulcerative Colitis in Adults: A Review. (JAMA, 2023) [PMID:37698559]
- AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. (Gastroenterology, 2024) [PMID:39572132]
- Ozanimod in UC Patients. (Gastroenterol Hepatol (N Y), 2023) [PMID:37711655]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. (2024) pubmed
- Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning. (2025) pubmed
- Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis. (2024) pubmed
- Ulcerative Colitis in Adults: A Review. (2023) pubmed
- Ozanimod in UC Patients. (2023) pubmed
- Update on ozanimod for ulcerative colitis. (2022) pubmed
- Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management. (2024) pubmed
- Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid. (2026) pubmed
- Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis. (2022) pubmed
- Analyses From the Phase 3 True North Study of Ozanimod in UC Patients. (2023) pubmed